Drug intelligence / Profile preview

HT-002

Development stage: Preclinical
Lead developer: Hoth Therapeutics
Modality: Peptides

Overview

HT-002 is a novel peptide therapeutic developed by researchers at Virginia Commonwealth University (VCU), including Dr. Michael Peters, and exclusively licensed by Hoth Therapeutics. It is designed to inhibit the SARS-CoV-2 virus by targeting its spike protein. The peptide acts as an ACE2 decoy, blocking the spike protein from binding to human ACE2 receptors and thereby preventing viral entry into cells. Its primary indication is for the treatment of COVID-19, including its variants.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on HT-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HT-002.

Explore the full profile